---
title: "Skye Licenses Halozyme's ENHANZE Drug Delivery Technology For Obesity Treatment"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/271515797.md"
description: "Halozyme Therapeutics, Inc. (HALO) has entered a global collaboration and license agreement with Skye Bioscience, Inc. (SKYE) to develop and commercialize higher-dose, subcutaneous administration strategies for nimacimab using Halozyme's ENHANZE drug delivery technology. Skye will make milestone payments and Halozyme will receive mid-single digit royalties on net sales for at least 10 years. Skye plans to start a Phase 2b clinical trial for nimacimab in obesity by mid-2026. In pre-market trading, HALO is at $70.46 (+0.21%) and SKYE at $0.97 (+11.44%)."
datetime: "2026-01-05T12:55:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271515797.md)
  - [en](https://longbridge.com/en/news/271515797.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271515797.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/271515797.md) | [繁體中文](https://longbridge.com/zh-HK/news/271515797.md)


# Skye Licenses Halozyme's ENHANZE Drug Delivery Technology For Obesity Treatment

Add  as your preferred news source on Google

 Add Now

Halozyme Therapeutics, Inc. (HALO), Monday announced a global collaboration and license agreement with Skye Bioscience, Inc. (SKYE) regarding development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab.

Under this agreement, Skye has licensed Halozyme's ENHANZE drug delivery technology, intending to expand the reach of this technology into the growing obesity market.

Also, Skye intends to evaluate multiple dose-ranging strategies, including in combination with GLP-1 receptor agonists.

As per the terms of the deal, Skye will make milestone payments tied to the achievement of certain development and commercialization events.

Additionally, Halozyme will be entitled to mid-single digit royalties on net sales of nimacimab developed with ENHANZE for at least 10 years.

Meanwhile, Skye plans to commence a Phase 2b clinical trial in obesity for nimacimab with ENHANZE in the middle of 2026.

In the pre-market hours, HALO is trading at $70.46, up 0.21 percent, and SKYE is trading at $0.97, up 11.44 percent on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

### 相关股票

- [Halozyme Therap (HALO.US)](https://longbridge.com/zh-CN/quote/HALO.US.md)
- [Skye Bioscience (SKYE.US)](https://longbridge.com/zh-CN/quote/SKYE.US.md)

## 相关资讯与研究

- [BUZZ-Skye Bioscience rises as it begins testing higher doses of obesity drug](https://longbridge.com/zh-CN/news/281517563.md)
- [Skye Bioscience announces annual shareholder meeting via webcast](https://longbridge.com/zh-CN/news/281794174.md)
- [Fosun Pharmaceutical's Subsidiary Gets Nod for Phase I Trial for Breast Cancer Drug](https://longbridge.com/zh-CN/news/281480931.md)
- [EXCLUSIVE-Amazon says it has reached deal with US Postal Service on package deliveries](https://longbridge.com/zh-CN/news/281790432.md)
- [UK Regulator OKs Bayer's Treatment for Advanced Non-small Cell Lung Cancer](https://longbridge.com/zh-CN/news/281501722.md)